Under copyright Constraint(s) on Use: This work is protected by the U.S. Copyright Law (Title 17, U.S.C.). Use of this work beyond that allowed by "fair use" or any license applied to this work requires written permission of the copyright holder(s). Responsibility for obtaining permissions and any use and distribution of this work rests exclusively with the user and not the UC San Diego Library. Inquiries can be made to the UC San Diego Library program having custody of the work. Use: This work is available from the UC San Diego Library. This digital copy of the work is intended to support research, teaching, and private study.
Rights Holder and Contact
UC Regents
Description
In a small, clinical trial, a single dose of the drug suramin produced measurable, but transient, improvements in five boys with autism spectrum disorder (ASD). Here, lead researcher Robert K. Naviaux, MD, PhD, talks with Miles McInerney, a teenager with ASD who was involved in the study but did not receive suramin, and his mother, Kim Kennedy. They discuss the trial, why Miles wanted to participate, and his concerns about changing what makes him who he is. (Suramin is a 100-year-old drug developed to treat African sleeping sickness. It is not approved for any therapeutic use in the U.S. This trial was only intended to test the drug’s safety. Larger, longer clinical trials are needed to assess suramin or similar drugs as an ASD treatment. Born digital Special Collections & Archives, UC San Diego, La Jolla, 92093-0175 (https://lib.ucsd.edu/sca) [Title, Date]. N Equals One. Special Collections & Archives, UC San Diego. [Digital Object URL] Episode 17
Type
sound
Identifier
ark:/20775/bb20604780
Language
English
Subject
Suramin Drug repurposing Spectrum disorder Autism Podcast Clinical trials University of California, San Diego
If you're wondering about permissions and what you can do with this item, a good starting point is the "rights information" on this page. See our terms of use for more tips.
Share your story
Has Calisphere helped you advance your research, complete a project, or find something meaningful? We'd love to hear about it; please send us a message.
